Novartis v. Torrent: Consent Judgment in Heart Drug Patent Case
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novartis AG v. Torrent Pharmaceuticals, Ltd. |
| Case Number | 1:21-cv-01794 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2021 – Jul 2024 2 years, 6 months |
| Outcome | Plaintiff Win — Sealed Consent Judgment & Injunction |
| Patents at Issue | |
| Accused Products | sacubitril/valsartan tablets (24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg) |
Case Overview
The Parties
⚖️ Plaintiff
A Swiss multinational pharmaceutical company and one of the world’s leading patent holders in cardiovascular therapeutics.
🛡️ Defendant
An India-based generic pharmaceutical manufacturer with significant U.S. market ambitions, filing an ANDA for sacubitril/valsartan tablets.
Patents at Issue
This landmark case involved U.S. Patent No. 11,058,667 B2, covering formulation or composition aspects of sacubitril/valsartan combination therapy. As a late-filing continuation or related patent in the ENTRESTO® family, it represents Novartis’s effort to extend and reinforce its IP protection beyond earlier foundational patents — a common and legitimate strategy in pharmaceutical patent prosecution.
- • US 11,058,667 B2 — Covers formulation/composition aspects of sacubitril/valsartan
Developing a similar drug?
Check if your drug formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded with a **sealed Consent Judgment and Order of Injunction**, signed by Judge Andrews on July 8, 2024. The injunctive component is significant: it restrains Torrent from commercially manufacturing, using, selling, or offering for sale its sacubitril/valsartan ANDA products in the United States during the remaining enforceable term of U.S. Patent No. 11,058,667 B2, absent specific carve-outs negotiated between the parties. The specific terms remain sealed.
Key Legal Issues
The resolution — a consent judgment carrying injunctive relief — signals Novartis’s continued and aggressive defense of the ENTRESTO® franchise against generic entrants. The consent judgment — rather than a litigated finding on validity or infringement — suggests Torrent may have concluded that the strength of the ‘667 patent’s claims, combined with Novartis’s extensive litigation resources and the MDL coordination, made a full trial unfavorable. Alternatively, the parties may have negotiated a commercial resolution, potentially including a future authorized entry date, that served both parties’ business interests better than prolonged litigation.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical patents. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in cardiovascular patents
- Understand formulation claim patterns
🔍 Check My Drug’s Risk
Run a comprehensive FTO analysis for your own drug or product.
- Input your drug formulation or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Late-Stage Formulation Patents
MDL Coordinated Litigation
Multiple generic challengers
Sealed Settlement
Negotiated market entry
✅ Key Takeaways
Sealed consent judgments with injunctions are highly favorable outcomes for patent holders — blocking generic entry without creating adverse public claim construction rulings.
Search related case law →Delaware’s MDL coordination mechanism is a powerful enforcement tool for originator pharmaceutical companies facing multiple ANDA challengers.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. 11,058,667 B2 (application US15/572,399), covering aspects of sacubitril/valsartan combination therapy marketed as ENTRESTO®.
The case resolved via a sealed Consent Judgment and Order of Injunction entered by Judge Richard G. Andrews on July 8, 2024, restricting Torrent’s ability to market its generic sacubitril/valsartan tablets.
This case was coordinated with In re: Entresto Patent Litigation, MDL No. 1:20-md-02930-RGA, which consolidates multiple ANDA-related patent challenges to Novartis’s ENTRESTO® franchise in the District of Delaware.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court, District of Delaware — Case 1:21-cv-01794
- In re: Entresto (Sacubitril/Valsartan) Patent Litigation, MDL No. 1:20-md-02930-RGA
- USPTO Patent Center — U.S. Patent No. 11,058,667 B2
- Hatch-Waxman Act (35 U.S.C. § 271(e)(2))
- PatSnap — IP Intelligence Solutions for Pharmaceutical Companies
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.